<DOC>
	<DOCNO>NCT02613650</DOCNO>
	<brief_summary>This Phase 1b , open label , dose-finding study determine Maximum Tolerated Dose ( MTD ) MEK162 combination mFOLFIRI , evaluate response rate , clinical benefit rate additional safety parameter treatment combination</brief_summary>
	<brief_title>A Trial mFOLFIRI With MEK162 Patients With Advanced KRAS Positive Metastatic Colorectal Cancers</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Age &gt; 18 year old Patients histologically confirm KRAS positive metastatic colorectal cancer . Patients must progress firstline treatment metastatic disease oxaliplatin fluoropyrimidines base chemotherapy ( failure within six month ) candidate oxaliplatin ( i.e . neuropathy ) . ECOG Performance Status 01 Able provide inform consent willing sign approve consent form conform federal institutional guideline . Women childbearing potential must negative blood pregnancy test screen visit Adequate bone marrow , organ function laboratory parameter define protocol Adequate cardiac function define protocol Must recover adverse effect prior surgery , radiotherapy antineoplastic therapy . Alopecia CTCAE grade 1 peripheral neuropathy acceptable Willingness ability comply study procedures able take oral medication Dose Expansion Phase Additional Inclusion Criteria Patients must willing able undergo biopsy accord institute 's guideline requirement procedure Patients must measurable disease define RECIST v1.1 ( least one lesion ≥ 10mm least one dimension assess CT MRI , cutaneous lesion clearly define margin measure ≥ 10 mm least one dimension ) Patients must irinotecan refractory . Patients must progress prior irinotecan therapy must able tolerate standard irinotecan dos . UGT1A1 *28 homozygous patient Previous treatment MEK inhibitor Treatment systemic antineoplastic therapy ( include unconjugated therapeutic antibody toxin immunoconjugates ) investigational therapy within 4 week ( &lt; 6 week nitrosurea mitomycinC , antibody except trastuzumab ) within 5half life investigational therapy prior start study treatment , whichever longer Patient receive radiotherapy within 2 week prior first dose study treatment except localize radiation therapy symptomatic bone metastasis . Have diagnosis another malignancy , unless patient diseasefree least 3 year follow completion curative intent therapy , follow exception : Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , eligible study definitive treatment condition complete . Patients organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA ) value also eligible study hormonal therapy initiate radical prostatectomy perform . History current evidence retinal vein occlusion ( RVO ) current risk factor RVO ( e.g . uncontrolled glaucoma ocular hypertension , history hyperviscosity hypercoagulability syndrome . Personal history Gilbert 's syndrome . Uncontrolled arterial hypertension define blood pressure &gt; 140 ( systolic ) or100 ( diastolic ) mmHg rest ( average 3 consecutive reading least 5 minute apart ) despite appropriate medical therapy . Impaired cardiovascular function clinically significant cardiovascular disease , include follow : History acute coronary syndrome ( include myocardial infarction , unstable angina , coronary artery bypass grafting , coronary angioplasty , stenting ) &lt; 6 month prior screen , Symptomatic chronic heart failure ; evidence clinically significant cardiac arrhythmia and/or conduction abnormality &lt; 6 month prior screen except atrial fibrillation paroxysmal supraventricular tachycardia . Known positive serology HIV , active Hepatitis B , and/or active Hepatitis C infection ( Note : suspect , test require baseline ) . Patients neuromuscular disorder associate elevated CK ( e.g. , inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) . Patients plan embark new strenuous exercise regimen first dose study treatment . Muscular activity , strenuous exercise , result significant increase plasma CK level avoid MEK162 treatment . Impairment gastrointestinal function gastrointestinal disease ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection judgment PI may impair absorption study drug ) . Any condition would , Investigator 's judgment , contraindicate patient 's participation clinical study due safety concern compliance clinical study procedure , e.g. , infection/inflammation , intestinal obstruction , unable swallow medication . ( patient may receive drug feed tube ) , social/ psychological issue , etc . Patients undergone major surgery ≤ 3 week prior start study drug recover side effect procedure . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception throughout study 15 day study drug discontinuation . Sexually active male unless use condom intercourse take drug 15 day stop treatment father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid . Medical , psychiatric , cognitive condition may compromise patient 's ability understand patient information , give informed consent , comply study protocol complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>